Portal Biotechnologies, Inc.

Portal Biotechnologies is a US-based company specializing in next-generation cell engineering solutions for personalized medicine, focusing on drug discovery and innovative applications in the biopharmaceutical sector. Portal Biotechnologies, Inc. was founded in 2023 and is headquartered in Watertown, US. The company focuses on advanced cell engineering techniques for drug discovery.

It has successfully completed 2 deals as of now, with its latest funding round being a Seed round in December 2024, where it raised USD 11. 695 mn led by IA Ventures with additional participation from Pear VC and others. The firm has a current valuation of USD 30. 048 mn.

Portal Biotechnologies specializes in next-generation cell engineering and drug discovery, focusing on innovative solutions for personalized medicine. The company’s core product offerings include proprietary membrane technology that facilitates mechanical disruption for efficient cargo delivery into cells. This technology is designed to enhance drug discovery processes and improve cell therapy applications, particularly for engineered red blood cells (RBCs) that serve as antigen carriers to drive T cell responses against tumors. Portal's products target biopharma and academic institutions globally, enabling researchers and developers to explore advanced therapeutic modalities.

Key geographical markets for their solutions include North America, Europe, and select regions in Asia, where demand for cutting-edge cell engineering tools is rapidly growing. Portal Biotechnologies generates revenue through a combination of partnerships and collaborations with biopharma companies and academic institutions. The transaction structure primarily involves B2B agreements, where clients engage in contractual partnerships to utilize Portal's cell engineering technologies in their research and development projects. Revenue is further supported by participation in government grants and contracts, including a notable USD 8 mn DARPA contract aimed at advancing cell therapy production capabilities.

Clients benefit from tailored solutions that enhance their drug development pipelines, with a focus on scalability and customization to meet specific therapeutic needs. This strategic approach ensures a steady revenue stream as the company continues to expand its client base and technological offerings in the evolving biopharmaceutical landscape. In December 2024, Portal Biotechnologies, Inc. raised USD 11.

69 mn in Seed funding led by IA Ventures, designed to support the introduction of next-generation products and foster sustained growth. The company plans to launch new products aimed at improving cell therapy applications by 2025. Additionally, Portal intends to expand its market reach into select regions in Asia and Europe within the next two years, leveraging the recent funding to enhance its technological capabilities and accelerate product development.